← Back to main page

Part 2: Antigen Selection Pipeline

2.1. Overview

In this section, we’ll develop a pipeline that suggests antigen candidates for an mRNA vaccine against Acinetobacter baumannii, a Gram-negative bacterium with the ability to thrive in a variety of environmental conditions. It is commonly found in hospital environments and causes infections such as meningitis, wound infections, and pneumonia. A. baumannii can spread through respiratory-care gear, wound-care instruments, humidifiers, surgical instruments, door knobs, and even mop heads. The bacteria usually target immunocompromised individuals, elevating morbidity and mortality rates by 26.5-91%. Broad-spectrum antibiotics are the most common form of treatment, yet the threat posed by the bacteria has grown significantly over the past 15 years as it has shown increasing resistance to most antibiotics. Currently, there are no vaccines against A. baumannii in phase I-III/clinical trials, which has been designated as a critical pathogen by WHO.

With that said, it’s time to start the most hands-on section of this guide. To make it easier to understand, what we’ll do will be explained along the way, with a final subsection dedicated to the overall picture.

2.2. Pipeline